Department of Scientific Research Project, Affiliated Zhongshan Hospital of Dalian University, Dalian, China
Department of Clinical Nutrition and Metabolism, Affiliated Zhongshan Hospital of Dalian University, Dalian, China.
BMJ Open. 2019 Oct 28;9(10):e032742. doi: 10.1136/bmjopen-2019-032742.
Metabolically healthy obese phenotype (MHO) refers to obese individuals with an adequate metabolic profile and absence of metabolic syndrome. Many prospective studies have reported the benign condition relating the MHO phenotype and its potential role in reducing risk of cardiovascular disease, total cancer, and all-cause and cause-specific mortality. However, inconsistent results were found and the question remains controversial. We aim to conduct a systematic review and meta-analysis to clarify the associations these associations from relevant prospective studies.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses for Protocols 2015 statement was used to prepare this protocol. MEDLINE, Web of Science databases, EMBASE and Cochrane Database will be used for literature search from their inception up to December 2019 with restriction of published studies in English. Published prospective studies reporting adjusted relative risk (RR) estimates for the association between MHO phenotype and cardiovascular disease, total cancer, all-cause or cause-specific mortality will be included. The process of study screening, selection and data extraction will be performed independently by two reviewers, and the risk of bias for the studies included will be assessed using the Newcastle-Ottawa Quality Assessment Scale. HRs or RRs for disease events and mortality with 95% CIs will be considered as primary outcomes, and summary HRs/RRs will be pooled using random-effects models. The Cochrane's Q and the I statistics will be used to assess and quantify heterogeneity, respectively. Subgroup analysis will also be carried out according to study characteristics to investigate potential sources of heterogeneity.
As this meta-analysis is performed based on the published studies, no ethical approval and patient safety considerations are required. The findings of the study will be reported and submitted to a peer-reviewed journals for publication.
CRD42019121766.
代谢健康型肥胖表型（MHO）是指代谢特征良好且不存在代谢综合征的肥胖个体。许多前瞻性研究报告了 MHO 表型与心血管疾病、总癌症、全因和死因特异性死亡率降低风险之间的良性关联及其潜在作用。然而，研究结果并不一致，该问题仍存在争议。我们旨在进行系统评价和荟萃分析，以阐明相关前瞻性研究中这些关联。
本研究方案采用了 2015 年系统评价和荟萃分析首选报告项目声明。将从 MEDLINE、Web of Science 数据库、EMBASE 和 Cochrane 数据库检索从成立到 2019 年 12 月的文献，限制使用英文发表的研究。纳入报告 MHO 表型与心血管疾病、总癌症、全因或死因特异性死亡率之间关联的调整相对风险（RR）估计值的前瞻性研究。研究筛选、选择和数据提取过程将由两名评审员独立进行，使用 Newcastle-Ottawa 质量评估量表评估纳入研究的偏倚风险。将疾病事件和死亡率的 HRs 或 RRs 及其 95%置信区间（CI）视为主要结局，并使用随机效应模型汇总 HRs/RRs。使用 Cochrane's Q 和 I 统计量分别评估和量化异质性。还将根据研究特征进行亚组分析，以调查异质性的潜在来源。
由于这项荟萃分析是基于已发表的研究进行的，因此不需要伦理批准和患者安全考虑。研究结果将报告并提交给同行评议的期刊发表。
PROSPERO 注册号：CRD42019121766。
